You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 11, 2025

Details for Patent: 3,415,821


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 3,415,821
Title:1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
Abstract:
Inventor(s):Davis Charles Stewert, Jr Harry Raymond Snyder
Assignee:Eaton Laboratories Inc, Warner Chilcott Pharmaceuticals Inc
Application Number:US485566A
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 3,415,821

Introduction

United States Patent 3,415,821, though not specifically detailed in the provided sources, can be analyzed using general principles of patent law and the processes involved in patent examination. Here, we will delve into the key aspects of patent scope, claims, and the broader patent landscape, using relevant examples and principles to illustrate the points.

Patent Scope and Claims

Definition of Patent Scope

Patent scope refers to the breadth and depth of protection granted by a patent. It is crucial in determining what is covered by the patent and what is not. The scope is primarily defined by the claims of the patent, which are the legal boundaries of the invention[5].

Metrics for Measuring Patent Scope

Research has identified simple metrics to measure patent scope, such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes. Narrower claims are often associated with a higher probability of grant and a shorter examination process[3].

The Importance of Claims in Patents

Claims as Boundaries of Protection

The claims section of a patent is the most critical part, as it defines what is protected by the patent. Claims must be clear, concise, and enabled, meaning they must teach a person with ordinary skill in the art how to make or use the invention[5].

Types of Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit an independent claim.

Claim Construction

The construction of claims is a delicate process. Claims that are too broad may be rejected for being overly broad or obvious, while claims that are too narrow may not provide sufficient protection. The examination process often narrows the scope of patent claims to ensure they are patentable[3].

Patent Examination and Prosecution

The Patent Examination Process

The U.S. Patent and Trademark Office (USPTO) examines patent applications to determine if the invention is novel, nonobvious, and enabled. This process can take several years and involves multiple rounds of arguments and amendments to the claims. If the examiner rejects the claims, the applicant can appeal to the Patent Trial and Appeal Board (PTAB) or the federal courts[5].

Patent Term Adjustment (PTA) and Terminal Disclaimers

Patent Term Adjustment (PTA) can extend the term of a patent due to delays in the examination process. However, terminal disclaimers, which are often used to overcome obviousness-type double patenting (ODP) rejections, can limit the term of a patent. The USPTO and courts have clarified that PTA does not extend the term past the date of a terminal disclaimer[1].

Obviousness-Type Double Patenting (ODP)

Definition and Impact

ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of PTA. This is crucial in ensuring that inventors do not extend the monopoly period of their inventions through multiple patents[1].

International and National Patent Applications

Provisional and Non-Provisional Applications

In the U.S., inventors can file a provisional patent application to temporarily protect their invention. This is followed by a non-provisional application within one year. For international protection, inventors can file a Patent Cooperation Treaty (PCT) application, which preserves the right to file in 153 countries within 30 months[5].

Costs and Commercial Considerations

The cost of patenting can be significant, ranging from $8,000 to $20,000 for a U.S. non-provisional application, and much more for international patents. Commercial partners often cover these costs, especially if there are near-term licensing opportunities[5].

Public Disclosure and Grace Periods

Public Disclosure Risks

Public disclosure of an invention before filing a patent application can jeopardize patent protection. In the U.S., there is a one-year grace period for filing after public disclosure, but most foreign countries have no such grace period[5].

Key Takeaways

  • Patent Scope: Defined by the claims, it is crucial for determining the breadth and depth of protection.
  • Claims: Must be clear, concise, and enabled to define the invention.
  • Patent Examination: Involves multiple rounds of arguments and amendments to ensure the invention is novel, nonobvious, and enabled.
  • PTA and Terminal Disclaimers: PTA extends the patent term due to examination delays, but terminal disclaimers can limit this extension.
  • ODP: Prevents extending the monopoly period through multiple patents.
  • International Applications: PCT applications provide global protection options.
  • Public Disclosure: Risks losing patent protection if not managed properly.

FAQs

Q: What is the primary function of claims in a patent? A: Claims define the boundaries of patent protection and must be clear, concise, and enabled.

Q: How does the USPTO determine if an invention is patentable? A: The USPTO examines the invention to ensure it is novel, nonobvious, and enabled.

Q: What is the difference between a provisional and non-provisional patent application? A: A provisional application provides temporary protection, while a non-provisional application is a formal application that can lead to a granted patent.

Q: What is Obviousness-Type Double Patenting (ODP)? A: ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a previously filed patent.

Q: Why is it important to manage public disclosure of an invention? A: Public disclosure before filing a patent application can risk losing patent protection, especially in countries without a grace period.

Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit
  2. U.S. Patent and Trademark Office (USPTO) - USA.gov
  3. Patent Claims and Patent Scope - SSRN
  4. An Evaluation of the Patent Portfolio Funded by the U.S. Department ... - Energy.gov
  5. Intellectual Property Protection - KU Office of Research

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 3,415,821

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

International Family Members for US Patent 3,415,821

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Austria 263759 ⤷  Try for Free
Belgium 686434 ⤷  Try for Free
Brazil 6682681 ⤷  Try for Free
Switzerland 483446 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.